| Tbio | Protein S100-A2 |
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer. [provided by RefSeq, Jul 2008]
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may have a tumor suppressor function. Chromosomal rearrangements and altered expression of this gene have been implicated in breast cancer. [provided by RefSeq, Jul 2008]
Comments
Property Summary
| NCBI Gene PubMed Count | 67 |
| Grant Count | 17 |
| R01 Count | 16 |
| Funding | $737,107.15 |
| PubMed Score | 88.29 |
| PubTator Score | 109.28 |
| Disease | log2 FC | p |
|---|---|---|
| malignant mesothelioma | -1.300 | 0.000 |
| esophageal adenocarcinoma | -3.800 | 0.032 |
| psoriasis | 2.300 | 0.000 |
| posterior fossa group A ependymoma | 2.300 | 0.000 |
| glioblastoma | 1.700 | 0.000 |
| atypical teratoid / rhabdoid tumor | 1.400 | 0.000 |
| medulloblastoma, large-cell | 1.100 | 0.023 |
| Atopic dermatitis | 1.500 | 0.000 |
| tuberculosis and treatment for 3 months | -1.200 | 0.000 |
| non-small cell lung cancer | 4.841 | 0.000 |
| colon cancer | 3.500 | 0.000 |
| ulcerative colitis | 1.500 | 0.000 |
| pancreatic cancer | 2.000 | 0.001 |
| adult high grade glioma | 1.500 | 0.004 |
| subependymal giant cell astrocytoma | 1.098 | 0.015 |
| lung adenocarcinoma | 2.500 | 0.000 |
| nasopharyngeal carcinoma | -1.700 | 0.021 |
| spina bifida | -2.475 | 0.049 |
| Breast cancer | -1.300 | 0.007 |
| ductal carcinoma in situ | 2.300 | 0.006 |
| ovarian cancer | 3.100 | 0.000 |
| PMID | Text |
|---|---|
| 25999659 | Data show higher expression level of S100A2 in high-invasive cholangiocarcinoma Cell Line suggesting it as potential marker of tumor progression and novel therapeutic target. |
| 25874882 | Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs. |
| 25591983 | The potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in oral squamous cell carcinoma patients. |
| 24556685 | These data demonstrate the importance of S100A2 downstream of the BRCA1/DeltaNp63 signalling axis in modulating transcriptional responses and enforcing growth control mechanisms through destabilisation of mutant p53. |
| 24318973 | loss of S100A2 expression contributes to Ggastric cancer development and progression. |
| 23996929 | S100A2 protumorigenic actions and its involvement in TGF-beta-mediated cancer cell invasion and epithelial-mesenchymal transition. |
| 23726265 | Data indicate that S100A2 expression predicts longer disease-free survival (DFS) and overall survival (OS) in patients treated with adjuvant therapy and should be evaluated as a predictive biomarker. |
| 23621473 | Expression of S100A2 in cholangiocarcinoma cells significantly correlated with the histological grade, lymph node metastasis, clinical stage, and a poor survival rate of the patients. Thus it is a strong tumor marker for the cancer. |
| 23344957 | Data indicate S100A2 and S100P proteins as novel Ca2+-dependent regulators of the CHIP-proteasome pathway. |
| 23337980 | In conclusion, data from the present study demonstrated that loss of S100A2 expression contributes to gastric cancer development and progression |
| More... |
| PMID | Year | Title |
|---|---|---|
| 25999659 | 2015 | Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion. |
| 25874882 | 2015 | iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein A2 in metastasis of laryngeal cancer. |
| 25591983 | 2015 | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients. |
| 25416956 | 2014 | A proteome-scale map of the human interactome network. |
| 24556685 | 2014 | S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. |
| 24318973 | 2014 | Clinical significance of S100A2 expression in gastric cancer. |
| 23996929 | 2014 | Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3. |
| 23726265 | 2013 | S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. |
| 23621473 | 2013 | Clinicopathological significance of S100 protein expression in cholangiocarcinoma. |
| 23344957 | 2013 | Ca2+/S100 proteins act as upstream regulators of the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein). |
| More... |
